4/18/2017
Pixabay

Bristol-Myers Squibb agreed to work with Nordic Bioscience to develop translational biomarkers and diagnostics for nonalcoholic steatohepatitis in preclinical and clinical models of fibrotic diseases. The collaboration will combine BMS' drug-development capabilities with Nordic's expertise in developing biomarkers and clinical trials.

Related Summaries